News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Jesus Anampa Mesias

Articles by Jesus Anampa Mesias

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath M. Jeselsohn,Pamela N. Munster, MD,Eric Zhi,Elizabeth Duperret,Cecile Mather,Erika P. Hamilton, MD,Hyo S Han

August 4th 2024

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?

Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM

Silevertinib Displays Robust Antitumor Activity in EGFR-Mutated NSCLC

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

© 2025 MJH Life Sciences^®

All rights reserved.